A recent retrospective analysis of the trial data demonstrated that SLT as a first-line treatment significantly outperforms glaucoma medications in reducing the rate of visual field (VF) loss.
Eye Drop Company Faces FDA Scrutiny Again Over Unapproved ProductsSep 19, 2024The FDA has issued a warning letter to the Regenerative Processing Plant, manufacturer of Regener-Eyes Pro and Lite eye drops, for marketing unapproved products claiming to treat dry eyes.
Maestro®: The Sinusoidal IOLSep 18, 2024VSY Biotechnology introduced the Maestro® Sinusoidal IOL at ESCRS 2024, featuring SVT. This innovative trifocal lens enhances visual acuity, contrast sensitivity, and light transmission, offering a cutting-edge solution for presbyopia management.
FDA Clears IND Application for HG202 Gene Therapy in Wet AMDNov 06, 2024The U.S. FDA has granted investigational drug clearance for HG202, a pioneering CRISPR/Cas13Y RNA-editing therapy developed by HuidaGene to treat neovascular (wet) age-related macular degeneration (AMD).
Nicotine's Potential in Myopia Control: Animal Research FindingsSep 27, 2024Researchers led by Dr. Kate Thomson from the University of Canberra have found that nicotine, when administered either as an intravitreal injection or topical eye drop, significantly inhibited the development of FDM and LIM in chicks.
Lamprey's Eye Disease: Separating Fact from FictionSep 30, 2024Lamprey Eye Disease, also known as "Lamprey Disease," is a hoax that has been circulating on the internet for several years. The hoax claims that a parasitic fish known as the lamprey is responsible for a disease that can cause blindness in humans.